Spyre Therapeutics launches underwritten public offering of common stock
SYRE•Spyre Therapeutics launched an underwritten public offering of common stock, with proceeds earmarked for its immunology pipeline, including late-stage work on SPY072 in hidradenitis suppurativa. Pricing, size and timing were not disclosed.
1. Offering details
The underwriters have a 30-day option to buy up to 15% additional shares on the same terms. Jefferies, TD Cowen, Leerink Partners and Stifel are joint bookrunners, and LifeSci Capital is passive bookrunner. The deal terms remain subject to market conditions.
